Adipothera
Adipothera develops therapies targeting the stromal microenvironment to treat diseases driven by fibrosis and inflammation. Using AI, computation, and multi-modal datasets, the company generates and validates drug candidates aimed at repairing tissue rather than managing symptoms. Their approach focuses on stromal reprogramming for conditions such as radiation injury, lymphedema, and pathological bone formation.
Industries
N/A
Nr. of Employees
small (1-50)
Products
AT-001 (Topical)
A topical drug candidate designed for local delivery to stromal targets in conditions such as radiation injury and lymphedema.
AT-002 (Oral)
An oral drug candidate for systemic modulation of stromal activation, focused on mitigating flare events in FOP/HO.
AT-001 (Topical)
A topical drug candidate designed for local delivery to stromal targets in conditions such as radiation injury and lymphedema.
AT-002 (Oral)
An oral drug candidate for systemic modulation of stromal activation, focused on mitigating flare events in FOP/HO.
Expertise Areas
- Stromal biology therapeutics
- Fibrosis and inflammation drug development
- AI-based drug design
- Preclinical translational research
Key Technologies
- AI-driven drug discovery
- Computational protein–ligand modeling
- Preclinical pharmacology assays
- Multi-modal data analytics
News & Updates
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.